Roche Holding AG / Adaptive Biotechnologies Corp.

Solid Tumors (Neoantigen-Directed T-Cell Therapy)

2.0M US cases/yr

Disease Overview

Neoantigen-directed T-cell receptor (TCR) therapies aim to engineer a patient's own T cells to recognize tumor-specific mutations rather than shared tumor antigens, theoretically delivering precise antitumor activity in solid tumors that have resisted CAR-T approaches. The science is highly individualized, manufacturing-intensive, and operates across virtually all solid tumor types where neoantigens can be identified.

Competitive Landscape

When Roche/Genentech signed the Adaptive deal in January 2019, the personalized neoantigen TCR space was crowded with PACT Pharma, BioNTech, Gritstone bio, Achilles Therapeutics, Iovance, and Adaptimmune all developing variations of TCR-engineered or TIL-based personalized therapies. Adaptive's differentiation was its proprietary immunoSEQ and TruTCR platform — a high-throughput pairing of TCR sequences to specific antigens that promised faster vein-to-vein turnaround. The deal positioned Genentech, already a leader in tumor immunology via Tecentriq, to extend into cellular therapy without an internal cell-therapy build. After six years, the partnership produced one IND clearance in May 2023 but no late-stage assets. In August 2025 Genentech terminated effective February 2026, citing strategic refocus rather than safety — Adaptive received $33.7M wind-down revenue and reverted to MRD diagnostics as its core business. The termination paralleled Roche's April 2024 walkaway from Adaptimmune, signaling Roche's broader retreat from individualized cell therapy economics. Competing platforms (PACT, Gritstone) have similarly struggled to advance beyond Phase 1, leaving the personalized neoantigen TCR thesis largely unproven.